ArticleOphthalmology science
Explainable Artificial Intelligence-Assisted Exploration of Clinically Significant Diabetic Retinal Neurodegeneration on OCT Images.
Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Responsible artificial intelligence in medical imaging: a systematic review.Frontiers in digital health · 2026Pooled it
- Exploration of Morphological Characteristics in Diabetic Macular Ischemia Utilizing a Large Language Model-Assisted Knowledge Graph.Ophthalmology science · 2026Article
- A Comprehensive Review Comparing Artificial Intelligence and Clinical Diagnostic Approaches for Dry Eye Disease.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore clinically significant diabetic retinal neurodegeneration in OCT images using explainable artificial intelligence (XAI) and subsequent evaluation by retinal specialists. Design: A single-center, retrospective, consecutive case series. Participants: Three hundred ninety-seven eyes from 397 diabetic retinopathy patients for XAI-based screening and 244 fellow eyes for subjective human evaluation. Methods: We acquired 30° horizontal OCT images centered on the fovea. An artificial intelligence (AI) model was developed to infer visual acuity (VA) reduction using fine-tuned RETFound-OCT. Attention maps highlighting regions contributing to VA inference were generated using layer-wise relevance propagation. Retinal specialists assessed OCT findings based on salient regions indicated by XAI. Two newly described findings, a needle-like appearance of the ganglion cell layer (GCL)/inner plexiform layer (IPL) ("ice-pick sign") and dot-like alterations in the outer nuclear layer (ONL) ("salt-and-pepper sign"), were evaluated alongside 2 established findings: EZ disruption and choroidal hypertransmission. Main Outcome Measures: Identification of clinically significant OCT findings associated with diabetic retinal neurodegeneration. Results: The AI model effectively discriminated eyes with poor vision (decimal VA ≤0.5) from those with good vision (VA ≥1.0) (area under the receiver operating characteristic curve of 0.947). Explainable artificial intelligence-based attention maps highlighted salient regions in the GCL/IPL (65.2% or 70.0%), ONL (52.2% or 28.3%), EZ (39.1% or 21.7%), and choroid (26.1% or 5.00%) in eyes with poor or good vision, respectively. Subjective evaluation by retinal specialists revealed the frequencies of these 4 findings as follows: ice-pick sign (32.4%), EZ disruption (25.0%), salt-and-pepper sign (16.0%), and choroidal hypertransmission (13.5%). Eyes with decimal VA ≤0.9 had these findings more frequently than those with VA ≥1.0 ( Conclusions: Artificial intelligence-assisted exploration of OCT findings identified 2 established lesions and 2 novel OCT biomarkers indicative of clinically significant diabetic retinal neurodegeneration. Financial Disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.